Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute lymphoblastic leukemia: treatment.

E Frei, S E Sallan

    Cancer
    |August 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Significant advancements in Acute Lymphoblastic Leukemia (ALL) treatment have been made over 30 years. Research focuses on new chemotherapy, combination therapies, and supportive care, including bone marrow transplantation for ALL patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improved serodiagnosis of alveolar echinococcosis of humans using an in vitro-produced Echinococcus multilocularis antigen.

    Parasitology·2007
    Same author

    Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - similarity between human and rat systems.

    General physiology and biophysics·2007
    Same author

    Aminopterin-human serum albumin conjugate (AP-HSA): uptake and cytotoxic effects in tumor cell lines.

    International journal of clinical pharmacology and therapeutics·2002
    Same author

    Mode of action of methotrexate-albumin in a human T-cell leukemia line and activity against an MTX-resistant clone.

    Anti-cancer drug design·2002
    Same author

    The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2002
    Same author

    Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy.

    General physiology and biophysics·2002
    Same journal

    Toward exercise as standard care for older cancer survivors.

    Cancer·2026
    Same journal

    Maintenance therapy in gynecologic malignancies: Current and future state.

    Cancer·2026
    Same journal

    Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

    Cancer·2026
    Same journal

    Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

    Cancer·2026
    Same journal

    EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

    Cancer·2026
    Same journal

    Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

    Cancer·2026
    See all related articles

    Area of Science:

    • Hematology
    • Oncology
    • Immunology

    Background:

    • Acute Lymphoblastic Leukemia (ALL) treatment has seen substantial progress over three decades.
    • ALL research has significantly influenced the development of chemotherapy principles and definitions.
    • Understanding ALL pathogenesis and identifying prognostic subcategories are crucial for therapeutic advancements.

    Purpose of the Study:

    • To review the progress in Acute Lymphoblastic Leukemia (ALL) treatment.
    • To highlight the ongoing research in chemotherapy, supportive care, and bone marrow transplantation for ALL.
    • To discuss the implications of improved understanding of ALL pathogenesis and subcategories.

    Main Methods:

    • Review of treatment categories including remission induction, sanctuary site treatment, and cytoreductive therapy.

    Related Experiment Videos

  • Analysis of research focusing on new chemotherapeutic agents and combination therapies.
  • Examination of host-tumor interactions, immunologic responses, and supportive care advancements.

    • Main Results:

    • Major progress achieved in ALL treatment over the past 30 years.
    • Identification of immunologic and prognostic subcategories of ALL with therapeutic implications.
    • Ongoing research into novel agents, rational combination chemotherapy, and supportive care.

    Conclusions:

    • Continued progress in ALL treatment is driven by a deeper understanding of its pathogenesis and subcategories.
    • Future research directions include developing new chemotherapeutic agents and optimizing combination therapies.
    • Supportive care, including bone marrow transplantation, remains a critical component in managing ALL.